BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24025360)

  • 1. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
    Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
    Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farletuzumab in lung cancer.
    Thomas A; Maltzman J; Hassan R
    Lung Cancer; 2013 Apr; 80(1):15-8. PubMed ID: 23357463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
    Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
    Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
    Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
    Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
    Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
    Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farletuzumab in epithelial ovarian carcinoma.
    Spannuth WA; Sood AK; Coleman RL
    Expert Opin Biol Ther; 2010 Mar; 10(3):431-7. PubMed ID: 20092424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
    Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K
    Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
    Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
    Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
    Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
    Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
    Kamen BA; Smith AK
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys.
    Moriyama T; Kakiuchi D; Grasso L; Hutto DL; Fernando D; Schweizer C
    Reprod Toxicol; 2018 Aug; 79():89-95. PubMed ID: 29928988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of farletuzumab in epithelial ovarian carcinoma.
    Jelovac D; Armstrong DK
    Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement.
    Kline JB; Kennedy RP; Albone E; Chao Q; Fernando S; McDonough JM; Rybinski K; Wang W; Somers EB; Schweizer C; Grasso L; Nicolaides NC
    Oncotarget; 2017 Aug; 8(32):52045-52060. PubMed ID: 28881712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
    Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
    Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.